PCSK9 and hyperlipidemia: Because miR-483, a secretory miR, and circulatory levels of PCSK9 are increased in hyperlipidemic rodent models and human subjects (18, 20, 22), we investigated whether hyperlipidemia is associated with reduced levels of miR-483 in circulation.